Short Interest in Click Holdings Limited (NASDAQ:CLIK) Declines By 94.9%

Click Holdings Limited (NASDAQ:CLIK) saw a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 1,939 shares, a decrease of 94.9% from the June 30th total of 37,691 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily volume of 56,286 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on CLIK shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Click in a research note on Wednesday, June 24th. Wall Street Zen raised Click to a “hold” rating in a research note on Saturday, June 13th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Click stock. Renaissance Technologies LLC bought a new stake in Click Holdings Limited (NASDAQ:CLIK) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned about 1.23% of Click as of its most recent filing with the SEC.

Click Trading Up 1.9%

Shares of NASDAQ:CLIK traded up $0.03 during midday trading on Friday, reaching $1.63. 45,626 shares of the company were exchanged, compared to its average volume of 373,797. Click has a fifty-two week low of $1.32 and a fifty-two week high of $14.40. The stock has a fifty day simple moving average of $1.57 and a two-hundred day simple moving average of $2.70.

Click (NASDAQ:CLIK) last announced its earnings results on Monday, May 11th. The company reported $0.10 earnings per share for the quarter. The company had revenue of $3.79 million during the quarter.

Click Company Profile

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.